Search Results for "ATTRv"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Neurofilament Light Chain in ATTR Amyloidosis with Cardiomyopathy: Analysis from the Phase 3 APOLLO-B Study

Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External

V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.

Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank

Alnylam Act®: Effectiveness of Genetic Testing in Establishing a Diagnosis in Patients with Suspicion of Hereditary Transthyretin Amyloidosis

Effect and Safety of Patisiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Chronic Kidney Disease Results

Insights from the HELIOS-A Study

This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.

NfL as a Potential Biomarker in hATTR Amyloidosis

This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.

APOLLO-B, a Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis: Primary Long-term Results from the Open-label Extension Period

Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis

Vutrisiran: HELIOS-A Study

Standard response letter on vutrisiran and results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.